Patrick I. Borgen, MD

Articles by Patrick I. Borgen, MD

49 The PREDICT II Registry: A Prospective Study to Evaluate the Clinical Utility of a 7-Gene Predictive Biosignature on Treatment Decisions in Patients With Ductal Carcinoma In Situ

ByPatrick I. Borgen, MD,Pat W. Whitworth,Anna Daily,Karuna Mittal,Steven C. Shivers,Troy Bremer

June 23rd 2026

PREDICT II is a prospective 30-site observational registry enrolling 3000 women with DCIS to evaluate how a 7-gene biosignature (DCISionRT) impacts treatment recommendations for surgery, radiation, and hormonal therapy.

6 Treatment Outcomes of the KEYNOTE-522 Regimen in an Ethnically Diverse Patient Population

ByMukuhi Ng’ang’a,Susan Burdette-Radoux, MD,Abhigna Kodali,Gene Sobol,Michael Silver,Charusheela Andaz,Patrick I. Borgen, MD,Joshua Feinberg

August 27th 2024

The Evolution of Breast Cancer Care

ByPatrick I. Borgen, MD

February 13th 2020

ONCOLOGY sat down with Patrick I. Borgen, MD, to discuss the latest trends in surgical and medical oncology, the transformation of breast cancer treatment over the course of his career, and the role he played within that evolution.

Patrick I. Borgen, MD, Discusses Treatment Advances to Watch for in HER2-Positive Breast Cancer

ByPatrick I. Borgen, MD

December 19th 2019

The breast cancer expert discussed 2 advances in HER2-positive breast cancer treatment that healthcare providers should look for.

Patrick I. Borgen, MD, Discusses Upcoming Breast Cancer Conferences

ByPatrick I. Borgen, MD

December 3rd 2019

The breast cancer expert discussed the importance of attending breast cancer meetings like the San Antonio Breast Cancer Symposium and the Miami Breast Cancer Conference.

Managing Ductal Carcinoma In Situ in the Era of Genomic Profiling

ByPatrick I. Borgen, MD

March 20th 2018

At the 2018 Miami Breast Cancer Conference, Dr. Patrick Borgen presented information related to gene expression profiling as a tool for managing DCIS.